Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

Código QR

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

Bo AhrénDepartment of Clinical Sciences, Lund University, Lund, SwedenAbstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagonlike peptide-1 (GLP-1). This increases circulating levels of active GLP-1, stimulates insulin secretion and inhibits glucagon s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Ahren B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Glucagon-like peptide-1 dipeptidyl peptidase-4 type 2 diabetes sitagliptin treatment Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/c4c71a79f0684c539d5fe2472a069960
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Green J, et al.
Publicado: (2010)

The durability of sitagliptin in elderly patients with type 2 diabetes
por: Hsieh CJ, et al.
Publicado: (2014)

Adjunctive therapy for glucose control in patients with type 1 diabetes
por: Harris K, et al.
Publicado: (2018)

Incretin-based therapy: renal effects
por: Anton Ivanovich Korbut, et al.
Publicado: (2016)

Saxagliptin for type 2 diabetes
por: Chacra
Publicado: (2010)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin YH, et al.
Publicado: (2019)

Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
por: Elena Nikolaevna Trunina, et al.
Publicado: (2011)

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
por: Pearson S, et al.
Publicado: (2019)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Kushner P
Publicado: (2010)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han E, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Wang N, et al.
Publicado: (2019)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
por: Juris J. Meier
Publicado: (2019)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
por: Howell R, et al.
Publicado: (2019)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Bo Ahr&eacute;n
Publicado: (2010)

Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
por: Angelo Avogaro
Publicado: (2018)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Knop FK, et al.
Publicado: (2010)

Teneligliptin in management of type 2 diabetes mellitus
por: Sharma SK, et al.
Publicado: (2016)

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
por: Chen L, et al.
Publicado: (2020)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
por: Gagik Radikovich Galstyan, et al.
Publicado: (2015)

The associations of incretin hormone concentration with gestational diabetes mellitus
por: Tatiana V. Saprina, et al.
Publicado: (2016)

Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension
por: Cosenso-Martin LN, et al.
Publicado: (2020)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
por: Gagik R. Galstyan, et al.
Publicado: (2017)

Vildagliptin: the first innovative DDP-4 inhibitor
por: Edvin Villkhauer
Publicado: (2010)

Mild cognitive decline in type 2 diabetes mellitus patients – risk factors and pathogenesis: role of DPP4 activity and future possible therapeutic targets
por: Gul O, et al.
Publicado: (2019)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
por: Lee J, et al.
Publicado: (2019)

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population
por: Funch D, et al.
Publicado: (2021)

Is there an association between liraglutide use and female breast cancer in a real-world setting?
por: Funch D, et al.
Publicado: (2018)

Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
por: Orme ME, et al.
Publicado: (2017)

Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial
por: Zhang F, et al.
Publicado: (2021)

Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway
por: Civantos E, et al.
Publicado: (2017)

Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus
por: Le TD, et al.
Publicado: (2020)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
por: Nina A. Petunina, et al.
Publicado: (2018)

Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
por: Alexander Sergeevich Ametov, et al.
Publicado: (2010)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz B
Publicado: (2013)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
por: Kugler AJ, et al.
Publicado: (2018)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
por: Ekaterina Alekseevna Shestakova
Publicado: (2011)

Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
por: Hiroshi Kasamatsu, et al.
Publicado: (2021)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
por: Karyekar CS, et al.
Publicado: (2013)

Simultaneous Effect of Resveratrol and Probiotics on Insulin Resistance and Glucagon-Like Peptide (GLP-1) Levels in Diabetic Rats
por: A Pegah, et al.
Publicado: (2021)